Respiratory Syncytial Virus (RSV) Vaccines
As of July 22, 2021, the U.S. CDC says there are no Approved Respiratory Syncytial Virus (RSV) vaccines in the USA. The development of RSV vaccines has been identified as a priority for the WHO Initiative for Vaccine Research.
Results from a study published in the Journal of the Pediatric Infectious Diseases Society showed that 49,509 to 59,867 cases of community-onset RSV-associated hospitalizations occurred among children in this age group during the 2014-2015 RSV season — an estimate that might help inform vaccination strategies. “With RSV vaccines expected to be available in the upcoming years, it is important to establish nationally representative baseline estimates of RSV hospitalizations,” the study authors wrote.
RSV Vaccine Candidates
Meissa Vaccines MV-012-968 is an investigational, live attenuated vaccine for protection against respiratory syncytial virus infection.
ResVax is a vaccine candidate composed of recombinant RSV F nanoparticles adsorbed to aluminum phosphate. The F protein is essential to RSV infectivity and is the target of palivizumab.
DS-Cav1 was developed by VRC, NIAID, and is composed of the respiratory syncytial virus (RSV) fusion glycoprotein ectodomain assembled as a trimer stabilized in its prefusion native conformation with a foldon trimerization domain at the C-terminus and 4 internal mutations designated DS-Cav1 (4.1DHFR_RSVAF).
IVX-121, an RSV vaccine candidate, incorporates a stabilized prefusion F antigen licensed from NIAID/NIH (DS-CAV1). VLP technology further enhances the magnitude, quality, and durability of the response to the prefusion RSV F. The enhanced response to VLP-based prefusion F could be particularly important in older adult populations
RSVpreF vaccine candidate is currently in a phase 2b clinical trial in pregnant women in the USA.
A medication called SYNAGIS (palivizumab) is available to prevent severe RSV illness in certain infants and children who are at high risk for severe disease. This medication can help prevent serious RSV disease, but it cannot help cure or treat children already suffering from serious RSV disease, and it cannot prevent infection with RSV.
RSV Vaccine News
July 20, 2021 - The UK NHS reported during week #28, Respiratory Syncytial Virus positivity increased from 6.8% to 8.9%.
June 11, 2021 - The American Hospital Association reported that the CDC yesterday alerted clinicians to an increase in Respiratory Syncytial Virus since late March in certain Southern states. The common respiratory virus usually causes mild cold-like symptoms but can be serious, especially for infants and older adults.
June 10, 2021 - The U.S. CDC issued a health advisory to notify clinicians and caregivers about increased interseasonal respiratory syncytial virus (RSV) activity across parts of the Southern United States. In addition, due to this increased activity, CDC encourages broader testing for RSV among patients presenting with acute respiratory illness who test negative for SARS-CoV-2.
December 15, 2020 - GeneFirst Gets CE-IVD Mark for Coronavirus, Flu, RSV Combo Test Kit. The test kit, which provides results in under two hours, is PCR system-agnostic and is suitable for use with a range of instruments, including Roche's LightCycler, and Thermo Fisher Scientific's Applied Biosystems 7500, according to a GeneFirst spokesperson.
November 21, 2020 - ‘Good progress is being made in RSV prevention research. Mary T. Caserta, M.D., a pediatrics professor at the University of Rochester Medical Center, provided an update on several RSV investigational products and vaccines in development for infants and pregnant mothers during a virtual presentation.
November 18, 2020 - According to the Centers for Disease Control and Prevention, virtually all children get an RSV infection when they are two years old. Most of the time, RSV will cause a mild, cold-like illness, but it can also cause severe illnesses such as bronchiolitis and pneumonia.
NOTE: The WHO has engaged the Advancing Maternal Immunization (AMI) collaboration to develop a more detailed gap analysis describing the evidence, information, and policy needs of global and country decision-makers, public health program planners implementers who might be involved in decision-making, and introducing maternal RSV vaccines. AMI’s companion maternal RSV vaccine roadmap describes near- and mid-to-long-term activities required to generate key evidence and achieve the necessary conditions for advancing RSV maternal immunization in low- and middle-income countries.